Real-life Efficacy in Clinical Practice

Real-world efficacy in clinical practice: An overall clinical success rate of 85% in cSSTI^1,2

Prior antibiotic use in CAPTURE^1,* 

Antibiotics were administered prior to ZINFORO^® treatment in 80% of patients. Clinical success rates in these subgroups were as follows:

• Patients receiving ZINFORO^® monotherapy: 86%

• Patients receiving ZINFORO^® concurrently with other antibiotics: 84%

Rationale for ZINFORO^® use

In a recent retrospective study, the most common reason for using ZINFORO^® was disease progression following prior therapies.³  
 

Real-world efficacy in patients with comorbidities and renal insufficiency⁴
Overall clinical success rates for evaluable patients with cSSTI by the category of renal function in the CAPTURE study* is represented below.
 

Rates of Clinical Success for Evaluable Acute Bacterial Skin and Skin Structure Infection Patients
 

Adapted from Maggoire C, et al. 2015.
 

Dosage adjustments were required in patients with moderate to severe renal impairment (CrCl ≥15 mL/min to ≤50 mL/min) and ESRD, including in patients undergoing haemodialysis.⁵

Real-world efficacy was demonstrated in obese patients with similar clinical success rates versus in patients with a normal BMI in the CAPTURE study.^6,*^,†   

Clinical Success Rates for Patients With Normal BMI and Obese or Morbidly Obese BMI​​​​​​​

Adapted from Evans JD, et al. 2014.​​​

ZINFORO^® is suitable for patients across a range of BMIs and does not require dosing based on their weights.⁶
Above data are real-world and are, therefore, subject to potential confounding bias usually associated with observational research.

*CAPTURE was a retrospective cohort study relating to the current treatment practice in the United States. In CAPTURE, ‘clinical success’ was defined as clinical cure with no further need for antibiotic therapy or clinical improvement with switch to oral agents at the end of the ZINFORO^® treatment. As CAPTURE is a retrospective chart review study, it has the limitations inherent to this study design.^1
†Normal BMI: 18.5 kg/m² to ≤24.9 kg/m²; BMI in obese patients: ≥30 kg/m²; BMI in morbidly obese patients: ≥40 kg/m².⁶

BMI, body mass index; CAPTURE, Clinical Assessment Program and TEFLARO® Utilization Registry; CrCl, creatinine clearance; cSSTI, complicated skin and soft tissue infection; ESRD, end-stage renal disease.